Subscribe
scientist-istock-505918900
gevende / iStockphoto.com
6 February 2019Americas

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion ($3.3 billion) immunotherapy deal with Germany-based Merck KGaA.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages